Michelle Hure, MD
Dermatopathology · San Juan Capistrano, CANPI 1760656169
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Sun Pharmaceutical Industries Inc. accounts for 67.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $3,523, 6.6 times the $535 reported in 2019.
Across 37 payments — averaging $131.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$3K
- Incyte Corporation$402
- Merz North America, Inc.$235
- Galderma Laboratories, L.p.$214
- Prugen, Inc. Pharmaceuticals$137
- Bristol Myers Squibb$123
- plus $467 from 5 others
What the payments were for
- Consulting fees$2,80057%
- Travel & lodging$281%
- Food & beverage$2,05142%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 9 | $3,301 |
| Incyte Corporation | 4 | $402 |
| Merz North America, Inc. | 1 | $235 |
| Galderma Laboratories, L.p. | 6 | $214 |
| Prugen, Inc. Pharmaceuticals | 9 | $137 |
| Bristol Myers Squibb | 1 | $123 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| LEO Pharma Inc. | 1 | $113 |
| Regeneron Healthcare Solutions, Inc. | 2 | $95 |
| UCB, Inc. | 1 | $94 |
| Revance Therapeutics, Inc. | 2 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,879 in reported general payments places this provider in the 85th percentile of 76 dermatopathology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluorouracil | 11 | $725 |
| Clobetasol Propionate | 13 | $725 |
| Ketoconazole | 32 | $491 |
| Doxycycline Hyclate | 13 | $428 |
| Mometasone Furoate | 14 | $254 |
| Mupirocin | 18 | $112 |
Paid to pharmacies, not to this prescriber.
Other dermatopathology in San Juan Capistrano
- Christiane QuerfeldDuarte$107K
- Brittney de ClerckLos Angeles$56K
- Brook Brouhala Jolla$20K
- Vishwas ParekhDuarte$13K
- Susan Detwilerla Jolla$7K
- Mandy Ramanila Canada$7K
- Curt VogelEncinitas$7K
- Karen Sherwoodla Canada$6K
- John Honchla Canada$6K
- Stacy WhitelockFullerton$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.